Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis
- PMID: 29940932
- PMCID: PMC6019800
- DOI: 10.1186/s12931-018-0831-y
Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis
Abstract
Background: Pulmonary fibrosis is a progressive and lethal disease characterized by damage to the lung parenchyma with excess extracellular matrix deposition. The involvement of endothelial cells in fibrosis development is unclear.
Methods: We isolated pulmonary endothelial cells, using a magnetic-activated cell sorting system, from mice with pulmonary fibrosis induced by intratracheal bleomycin. We characterized endothelial cells isolated at various times in the course of pulmonary fibrosis development.
Results: Inflammatory cell infiltration was observed at 7 days after bleomycin administration, and fibrotic changes with increased collagen content were observed on day 21. Endothelial cells were isolated at these two timepoints. Levels of von Willebrand factor, plasminogen activator inhibitor-1 and matrix metalloproteinase-12 were elevated in lung endothelial cells isolated from bleomycin-treated mice at days 7 and 21. This indicated that intratracheal bleomycin administration induced endothelium injury. Expression of fibrogenic mediators, transforming growth factor (TGF)-β, connective tissue growth factor and platelet-derived growth factor-C was elevated in the cells from bleomycin-treated, compared with untreated, lungs. When endothelial cells were treated with TGF-β, α-smooth muscle actin (SMA) expression and collagen production were increased only in those cells from bleomycin-treated mouse lungs. Thapsigargin-induced prostaglandin I2 and nitric oxide production, decreased in endothelial cells from bleomycin-treated mouse lungs, compared with controls, was further suppressed by TGF-β.
Conclusion: Bleomycin administration induced functional changes in lung endothelial cells, indicating potential involvement of endothelium in pulmonary fibrogenesis.
Keywords: Bleomycin; Endothelial cell; Fibrosis; Nitric oxide; Prostaglandin I2; TGF-β; α-SMA.
Conflict of interest statement
Ethics approval and consent to participate
This study was approved by the Animal Care and Use Committee of Hamamatsu University School of Medicine and all experiments were performed according to guidelines of this Committee.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures







Similar articles
-
Effect of Hypoxia on Pulmonary Endothelial Cells from Bleomycin-Induced Pulmonary Fibrosis Model Mice.Int J Mol Sci. 2022 Aug 12;23(16):8996. doi: 10.3390/ijms23168996. Int J Mol Sci. 2022. PMID: 36012260 Free PMC article.
-
Grape seed extract ameliorates bleomycin-induced mouse pulmonary fibrosis.Toxicol Lett. 2017 May 5;273:1-9. doi: 10.1016/j.toxlet.2017.03.012. Epub 2017 Mar 12. Toxicol Lett. 2017. PMID: 28300665
-
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.Respir Res. 2016 May 6;17(1):49. doi: 10.1186/s12931-016-0373-0. Respir Res. 2016. PMID: 27153807 Free PMC article.
-
Phosphoinositide 3-kinase γ plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice.J Leukoc Biol. 2011 Feb;89(2):269-82. doi: 10.1189/jlb.0610346. Epub 2010 Nov 2. J Leukoc Biol. 2011. PMID: 21048214
-
Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches.Cell Biochem Biophys. 2024 Sep;82(3):1845-1870. doi: 10.1007/s12013-024-01384-9. Epub 2024 Jul 2. Cell Biochem Biophys. 2024. PMID: 38955925 Review.
Cited by
-
Bleomycin-induced lung injury: Revisiting an old tool to model group III PH associated with pulmonary fibrosis.Pulm Circ. 2023 Jan 1;13(1):e12177. doi: 10.1002/pul2.12177. eCollection 2023 Jan. Pulm Circ. 2023. PMID: 36618712 Free PMC article.
-
Interstitial lung disease independently associated with higher risk for COVID-19 severity and mortality: A meta-analysis of adjusted effect estimates.Int Immunopharmacol. 2022 Oct;111:109088. doi: 10.1016/j.intimp.2022.109088. Epub 2022 Jul 27. Int Immunopharmacol. 2022. PMID: 35921779 Free PMC article.
-
Cell-Type-Specific Profibrotic Scores across Multi-Organ Systems Predict Cancer Prognosis.Cancers (Basel). 2021 Nov 30;13(23):6024. doi: 10.3390/cancers13236024. Cancers (Basel). 2021. PMID: 34885134 Free PMC article.
-
Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study.Respir Res. 2024 Jun 19;25(1):249. doi: 10.1186/s12931-024-02875-2. Respir Res. 2024. PMID: 38898447 Free PMC article.
-
Endothelial sensitivity to pro-fibrotic signals links systemic exposure to pulmonary fibrosis.Cell Death Dis. 2025 Jul 7;16(1):500. doi: 10.1038/s41419-025-07824-5. Cell Death Dis. 2025. PMID: 40623988 Free PMC article.
References
-
- American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. doi: 10.1164/ajrccm.165.2.ats01. - DOI - PubMed
-
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases